Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 50 of 71 entries
View as:

Observational Study of Neurofilament Light Chain (NfL) as a Biomarker in Asymptomatic Carriers of the Transthyretin (TTR) Variants and Patients With Hereditary Transthyretin-mediated (hATTR) Amyloidosis With Polyneuropathy

Phase: N/A Priority: Normal
NCT ID: NCT06360289 Org: User:
Start: 04/25/24 End: 12/01/27 Due: 12/01/28

A Phase 1 Study of an Investigational Drug, ALN-PCSSC, in Subjects With Elevated Low Density Lipoprotein Cholesterol (LDL-C)

Phase: N/A Priority: Normal
NCT ID: NCT02314442 Org: User:
Start: 12/31/14 End: 11/30/15 Due: 11/30/16

Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program

Phase: N/A Priority: Normal
NCT ID: NCT05040373 Org: User:
Start: 08/01/20 End: 10/12/30 Due: 10/12/31

ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)

Phase: N/A Priority: Normal
NCT ID: NCT04883905 Org: User:
Start: 04/26/21 End: 04/01/27 Due: 04/01/28

A Study to Evaluate Long-term Safety and Clinical Activity of Givosiran (ALN-AS1) in Patient With Acute Intermittent Porphyria (AIP)

Phase: N/A Priority: Normal
NCT ID: NCT02949830 Org: User:
Start: 10/31/16 End: 11/05/21 Due: 11/05/22

A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM

Phase: N/A Priority: Normal
NCT ID: NCT05761301 Org: User:
Start: 03/10/23 End: 04/03/25 Due: 04/03/26

A Study to Evaluate ALN-XDH in Healthy Subjects and Patients With Gout

Phase: N/A Priority: Normal
NCT ID: NCT05256810 Org: User:
Start: 02/25/22 End: 01/25/23 Due: 01/25/24

A Phase 1/2 Study of an Investigational Drug, ALN-CC5, in Healthy Adult Volunteers and Patients With PNH

Phase: N/A Priority: Normal
NCT ID: NCT02352493 Org: User:
Start: 01/31/15 End: 08/31/17 Due: 08/31/18

A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease

Phase: N/A Priority: Normal
NCT ID: NCT06585449 Org: User:
Start: 10/14/24 End: 07/05/28 Due: 07/05/29

Trial to Evaluate Safety and Tolerability of ALN-PCS02 in Subjects With Elevated LDL-Cholesterol (LDL-C)

Phase: N/A Priority: Normal
NCT ID: NCT01437059 Org: User:
Start: 09/30/11 End: 09/30/12 Due: 09/30/13

A Study of an Investigational Drug, ALN-AAT, in Healthy Adult Subjects and Patients With ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease

Phase: N/A Priority: Normal
NCT ID: NCT02503683 Org: User:
Start: 07/09/15 End: 01/03/18 Due: 01/03/19

Phase 2b Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)

Phase: N/A Priority: Normal
NCT ID: NCT01065935 Org: User:
Start: 02/28/10 End: 05/31/12 Due: 05/31/13

Multi-center, Open Label, Extension Study of ALN-VSP02 in Cancer Patients Who Have Responded to ALN-VSP02 Treatment

Phase: N/A Priority: Normal
NCT ID: NCT01158079 Org: User:
Start: 07/31/10 End: 09/30/12 Due: 09/30/13

A Study to Evaluate ALN-AGT01 RVR in Adult Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT06675565 Org: User:
Start: 11/05/24 End: 09/08/25 Due: 09/08/26

A Study of ALN-HBV in Healthy Adult Volunteers and Non-cirrhotic Patients With Chronic Hepatitis B Virus (HBV) Infection

Phase: N/A Priority: Normal
NCT ID: NCT02826018 Org: User:
Start: 06/24/16 End: 10/31/17 Due: 10/31/18

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALN-TTRSC04 in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT05661916 Org: User:
Start: 01/16/23 End: 09/01/25 Due: 09/01/26

Phase 2 Study to Evaluate ALN-TTRSC (Revusiran) in Patients With Transthyretin (TTR) Cardiac Amyloidosis

Phase: N/A Priority: Normal
NCT ID: NCT01981837 Org: User:
Start: 12/31/13 End: 01/31/15 Due: 01/31/16

A Phase 1, Single- and Multi-Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered ALN-TTRSC (Revusiran) in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01814839 Org: User:
Start: 03/31/13 End: 05/31/15 Due: 05/31/16

Patisiran in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) Disease Progression Post-Liver Transplant

Phase: N/A Priority: Normal
NCT ID: NCT03862807 Org: User:
Start: 03/27/19 End: 10/20/20 Due: 10/20/21

A Study of ALN-AAT02 in Healthy Participants and Participants With ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease

Phase: N/A Priority: Normal
NCT ID: NCT03767829 Org: User:
Start: 12/05/18 End: 06/25/20 Due: 06/25/21

ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP)

Phase: N/A Priority: Normal
NCT ID: NCT03338816 Org: User:
Start: 11/16/17 End: 05/31/21 Due: 05/31/22

The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Participants Who Have Already Been Treated With ALN-TTR02 (Patisiran)

Phase: N/A Priority: Normal
NCT ID: NCT02510261 Org: User:
Start: 07/16/15 End: 11/23/22 Due: 11/23/23

Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)

Phase: N/A Priority: Normal
NCT ID: NCT00658086 Org: User:
Start: 04/30/08 End: 06/30/09 Due: 06/30/10

Expanded Access Protocol to Provide Lumasiran to Patients With Primary Hyperoxaluria Type 1

Phase: N/A Priority: Normal
NCT ID: NCT04125472 Org: User:
Start: - End: - Due: -

A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1

Phase: N/A Priority: Normal
NCT ID: NCT03681184 Org: User:
Start: 11/27/18 End: 01/12/24 Due: 01/12/25